Madrid, 15 July. (European Press) –
Clinical data analysis and patient engagement are key to transforming personalized medicine into an “unstoppable reality,” experts explained in the framework of “Day One in Personalized Medicine: Facts, Challenges and Opportunities,” which Roche is organizing in collaboration with the Digital Health Association’s approval.
“Technology combined with artificial intelligence has made medicine progress at a much faster rate. However, data analysis is the most important aspect along with the development of accurate diagnoses and innovative treatments to make personalized medicine an unstoppable reality,” emphasized Roche Farma’s Director of Medical Division, Beatrice Perez.
Along the same lines, Teresa Ramos, who is in charge of personalized medicine at Roche Pharma, added that “while the data is basic, the backbone of the entire medical process is the patient.” He defended this, saying, “The data belongs to the patient, and he freely decides whether to share it, and for this he must be aware of this and be fully aware of the importance of this fact.”
In this sense, all participating experts agreed to underline the security surrounding the transmission of health data and the enormous benefit that the existence of this information, for example for research purposes, posits, to society at large and to the individual himself.
Alfonso Valencia, Director of the Life Sciences Division of the National Supercomputing Center, stated in this regard that “it is essential that there is a positive public perception regarding data collection and analysis.”
For his part, Ignacio Medrano, neurologist and founder of Savana and Mendelian, concluded his intervention by emphasizing that “it is necessary not to obstruct the investigation with suspicion, as well as to protect all this medical practice within an ethical regulatory framework that explains what uses it should have and which it does not”, which is A concept approved by Joaquín Dopazo, Director of the Progreso y Salud Foundation and researcher in charge of Computational Medicine for IBIS Systems in Seville.
The importance of access to innovation
Fernando López Rios, Associate Physician of the Pathological Anatomy Service at the 12 de Octubre University Hospital in Madrid and Professor at CEU San Pablo, and Marie Luz Amador, Medical Director of the Spanish Association Against Cancer (AECC), agreed that better organization of the data would It helps patients have equitable access to precision medicine throughout the national territory.
“It is pointless to make an accurate diagnosis, if you cannot access the right medication. It is a fact that patients live longer and better thanks to the use of targeted therapies. Personalized medicine saves time and quality of life, therefore, it must be within the reach of all diseases,” he explained Amador.
In order to achieve this fairness, Jose Soto, managing director of the University of San Carlos Clinical Hospital and president of the Spanish Association of Health Directors (SEDISA), has called for management agreements with their own budgets for personalized medicine.
He noted that “it is necessary to change the concept and stop talking about spending. We must talk about the cost, which is closely related to the result obtained. Currently, it has already been noted that the application of personalized medicine is cost-effective.”
In addition, in this context, as the representative of the Spanish Breast Cancer Federation, Paula Gonzalez, has argued in the field of personalized medicine “the patient should not merely be a recipient of clinical decisions, but rather be an active subject in making these decisions about their health” in A model that must translate into “personal, interdisciplinary and more participatory care than ever before”.
“Patients and clinicians need to go hand in hand, and develop lines of research from the start. It is imperative that the patient is involved so that not only the physician’s criteria are prioritized, but also the vital needs of patients across the board, coordinating neurologist in the Multiple Sclerosis Unit,” said Virginia Mica, coordinating neurologist in the Multiple Sclerosis Unit. At the Hospital de la Princesa in Madrid, the medical process. The patients.”
In this regard, Eduardo Tisano, Director of the Clinical and Molecular Genetics Area at the Vall d’Hebron Hospital in Barcelona, stated that “it is necessary to change the vision in which only the outcome is evaluated and more attention is paid to the expectations of the patient.”
